Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged phosphatidylinositol 3-kinase α (PI3Kα) (E545K mutant) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.
Harbin Medisan Pharmaceutical Co. Ltd. has synthesized PPARδ agonists reported to be useful for the treatment of fibrosis, neurodegeneration, inflammation, cardiovascular, cerebrovascular, autoimmune and metabolic disorders.
MYC is a transcription factor that plays relevant roles in cellular processes such as glycolysis, development, cell differentiation or proliferation. Recent research has associated the transcriptional activity of MYC to the activation of T cells in multiple sclerosis.
Atopic dermatitis is a systemic inflammatory disorder where both innate immune cells such as dendritic cells (DCs) and adaptive immune cells, such as B and T cells, contribute to cutaneous inflammation. B and T lymphocyte attenuator (BTLA), highly expressed in mature DCs, is crucial to modulate the activity of all immune cells and acts as a co-inhibitory checkpoint receptor.
After a team at the Hospital Universitari Vall d’Hebron found that histone deacetylase 3 (HDAC3) has a role in the chronic inflammatory response in the central nervous system in models of traumatic brain injury, they investigated its role in autoimmune demyelination.
In work at Shanghai Curegene Pharmaceutical Co. Ltd., synthesis and optimization of a series of SARS-CoV-2 3CL protease (3CLpro, Mpro) inhibitors led to the identification of compounds [I], [II] and [III] as lead candidates suitable for further evaluation, based on their enzymatic IC50s (14, 12 and 8.6 nM, respectively), cellular EC50s (36, 26 and 52 nM, respectively) and human liver microsome (HLM) stability.
Researchers from Kyverna Therapeutics Inc. presented preclinical data for KYV-101, a first-in-class, fully human autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy being developed for the treatment of patients with B-cell-driven neurologic autoimmune diseases, including multiple sclerosis and myasthenia gravis.
Tessellate Bio BV has announced it is collaborating with CMRI (Children’s Medical Research Institute) and Omico (Australian Genomic Cancer Medicine Centre) to advance the understanding of the prevalence of alternative lengthening of telomeres (ALT) across tumor types and the genetic factors involved.
RSS
